Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Welcome, mdh137! You'll find this board a whole lot better than YMB.
That's what "they" want you to think...
It's simply price control to allow more accumulation for their buddies.
A Perfect Scenario...
Anavex presents great data at AAIC; price surges 2X or more; AF/JF/MD/CR release their anticipated hit piece; the cabal begins its short attack; Anavex then drops a bomb of a PR: PARTNERSHIP & P3, sending the shorts scrambling, trying to cover much higher and at a huge loss. Oooh, a short squeeze beginning at the top!
It could happen...
Android, from Investopedia...
What does 'Wash Trading' mean
Wash trading refers to buying shares through one broker and selling the shares through another broker. Wash trading is not legal, as it is performed to manipulate the market and encourage other investors to move into a buying position. A quick turnaround of positions is not considered wash trading, provided the transaction creates market risk for the trader and alters his market position.
BREAKING DOWN 'Wash Trading'
Also known as round trip trading, the act of wash trading allows traders to buy stocks and then sell them, giving the appearance of purchases and sales being made, but the trader does not incur any market risk or change in market position.
The Commodity Exchange Act
The Commodity Exchange Act (CEA) establishes regulations for the trading of commodity futures in the United States. Under the CEA, wash trading is illegal. The CEA was passed in 1936 and has been amended a number of times since its establishment. It replaced the Grain Futures Act of 1922. This Act provides the statutory framework under which the Commodity Futures Trading Commission (CFTC) operates. The CFTC was created in 1974 as a result of the CEA.
It certainly seems they are keeping it low for this last day of accumulation. I'd sure like to see the shorts begin covering in earnest this afternoon.
I use Vanguard; a company I've used way before there was such a thing as online trading. :) The only limit they impose for online orders is $5M, where you have to place those orders over the phone. It's certainly not a "trading" platform, but the fees are quite low, if you have large holdings with them.
Got my limit sell orders in place...starting at $50, just in case a huge surge happens when I'm not looking! :) It's quicker to edit orders than to create. GLTALs!
Nice! Hopefully, after next week, we'll get some MAINSTREAM press!
IMO, only with large cap stocks and ETFs, where the capitalization and volume keep the manipulation to a minimum.
Yes, but even some investors will inappropriately use stop-loss orders.
Poor guy who had his stop-loss orders hit just now...
Agreed... the Aricept P3 trial was halted and FDA approved after 6 months. I doubt it will take that long for 2-73...perhaps even this year (BTD/fast-track) if data is that great.
Anyone else here expecting substantial short covering tomorrow?
I recall Dr. M reporting a 400% improvement over donepezil with the 5-wk trial results, but I don't remember what test(s) that was.
Okay, that might explain the new requests for shares, but what about the 4M that are already short? They are apparently expecting not so good news. Seems like a foolish bet.
A concerning list of side affects with NAMZARIC...
WARNINGS AND PRECAUTIONS
Cardiovascular Conditions
NAMZARIC may have vagotonic effects on the sinoatrial and atrioventricular nodes manifesting as bradycardia or heart block. Bradycardia or heart block may manifest in patients both with and without known underlying cardiac conduction abnormalities. Syncopal episodes have been reported in association with the use of donepezil hydrochloride, an active ingredient in NAMZARIC.
Peptic Ulcer Disease and Gastrointestinal Bleeding
Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult
gastrointestinal bleeding, especially those at increased risk for developing ulcers, those with a history of ulcer disease, or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs).
Nausea and Vomiting
NAMZARIC can cause diarrhea, nausea, and vomiting. Although in most cases, these effects have been mild and transient, sometimes lasting one to three weeks, and have resolved during continued use of donepezil hydrochloride, patients should be observed closely at the initiation of treatment.
Genitourinary Conditions
NAMZARIC may cause bladder outflow obstructions. Conditions that raise urine pH may decrease the urinary elimination of memantine, an active ingredient in NAMZARIC, resulting in increased plasma levels of memantine.
Seizures
Cholinomimetics, including donepezil hydrochloride, are believed to have some potential to cause generalized convulsions. However, seizure activity also may be a manifestation of Alzheimer's disease.
Pulmonary Conditions
Cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.
ADVERSE REACTIONS
•The most common adverse reactions, occurring at a frequency of at least 5% in patients taking memantine hydrochloride extended-release 28 mg/day, and greater than placebo, were headache (6% vs 5%), diarrhea (5% vs 4%), and dizziness (5% vs 1%).
•The most common adverse reactions, occurring at a frequency of at least 5% in patients taking donepezil, and at twice or more the rate of placebo, were diarrhea (10% vs 4%), anorexia (8% vs 4%), vomiting (8% vs 4%), nausea (6% vs 2%), and ecchymosis (5% vs 2%).
That would certainly be the optimal scenario; however, at some point the buying will subside and the shorting cabal will begin an attack, but they won't be as successful this time.
One reason, and possibly the primary reason, for the timing of the new agreement is that the old agreement was expiring this month. But I DO like the terms... indicates to me that the plans are materializing.
Good data will surely cause a spike up. So, to short at this lower level will likely cause a short squeeze that will assist the spike. If there was a planned attack, it would seem it would be this week in order to profit; otherwise, they would wait to short and attack AFTER the spike.
What do people make of the growing number of shares short (~4M) and the continued requests to borrow shares? Seems crazy...
Are these short bets against the news or are they mainly hedges (insurance) against long positions? If short bets, it seems they are ill informed and just going with the probability from past Alz trials.
Thoughts?
I would only consider selling if the price would double ahead of news, and then no more than half of my shares. I doubt that will happen.
Not sure about the rest of you, but I like the contained PPS, below $8, so far this week. Had it run up 15% per day as someone was projecting, I might be compelled to sell at week's end. With it maintaining below $8, I'm holding through news...at least.
Anavex's 2-73 is not the only drug being trialed in Australia. There are two others, I believe, including Lilly's drug. Can you confirm the article is referring to 2-73?
From the article...
"Despite its importance, the fundamental mechanism of how protein fibrils can self-replicate without any additional machinery is not well understood. In a study published today in the journal Nature Physics, a team led by researchers from the Department of Chemistry at the University of Cambridge used a powerful combination of computer simulations and laboratory experiments to identify the necessary requirements for the self-replication of protein fibrils."
So, are the proteins self-replicating or might they continue to produce because of growing stressed cells via neuroinflamation? If the decline in cell health is exacerbated with age, then it might appear the amyloid plaque is replicating, when in fact it is being produced by more dying cells, which are unable to slough off or prevent the misfolded proteins. The MoA of 2-73 is maintaining cell health.
Correct on the first impression (2 poster presentations) is a very good indicator. The 1-hr time frame is for the entire conference hall session. All posters in that session are on display for the full hour, while attendees come and go.
Might the cabal work to pump up the PPS in the next couple of days (a la CTAD) as another attempt to get holders to sell...fearful of another selloff prior to news? Who knows what game they might try to play this time?
Agreed... though would have liked to had both! :)
Perhaps with "normal" trading it could/should rise next week, but the cabal may try to drive it down to shake out as many retail shares as possible before the news. We'll just have to see how it plays out.
That's true. Preso on Wednesday is at 1:30p
I doubt we hear anything prior to the presentation. Could see a PR the following Monday...but certainly by Wednesday (27th)!
With lack of any news next week, it's possible that the criminal cartel might attack all week long, trying to drive out retail, prior to the conference. We shall see... seems they are looking for shares to borrow.
Indeed, holding options is very dangerous with microcap biotechs, because of the blatant manipulation involved. In-the-money options are your safer bets: reduced gains, but also reduced risks.
Roth or Traditional? If the latter, you could have converted it into Roth when it was in the 3s. That's what I did.
Same reason heroin addicts keep taking heroin when they know it can be dangerous. They can't resist.
Thank you, Xena. Many of us here value your insights and contributions.
Taken from the AAIC site... Appears I was a little off on my recollection, regarding the last paragraph.
Note: AAIC 2016 Developing Topic abstracts will be considered for poster presentation only unless the research is considered to be late-breaking.
Criteria:
* Late-breaking research/newness of information.
* Potential impact on the research community.
* Quality of scientific research.
* Relevance to Alzheimer's disease and related disorders.
* Topics of interest include basic and translational science, diagnosis and prognosis, therapeutics, and public health and psychosocial issues.
Additional information:
* Previously submitted/reviewed abstracts will not be considered.
* A limited number of abstracts are selected, with selection based on timeliness and scientific merit.
* Only under extraordinary circumstances will abstracts without results be considered.
* Accepted abstracts are published in an online supplement to the * Association's journal, Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
* Developing Topic abstracts must be submitted via the online system.
* Developing Topic abstracts are not accepted for the Alzheimer's Imaging Consortium or Technology and Dementia.
* Developing Topic abstracts do not include the AAIC Featured Research Session format.
* An individual may be the presenting author on one oral presentation (includes a featured research session) and two posters slotted on different days. Exception: An author may present in two oral platforms as long as one is a Developing Topic session.
Also, I thought I read on the AAIC site where a sponsor (company) could not have an oral presentation on the same day and same topic as its poster(s); therefore, to qualify for an oral would require a separate day and topic...which they don't have.